Jazz Pharmaceuticals (STU:J7Z) Accounts Payable : €74 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Accounts Payable?

Jazz Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2024 was €74 Mil.

Jazz Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2023 (€103 Mil) to Dec. 2023 (€94 Mil) and declined from Dec. 2023 (€94 Mil) to Mar. 2024 (€74 Mil).

Jazz Pharmaceuticals's annual Accounts Payable declined from Dec. 2021 (€89 Mil) to Dec. 2022 (€86 Mil) but then increased from Dec. 2022 (€86 Mil) to Dec. 2023 (€94 Mil).

Jazz Pharmaceuticals Accounts Payable Historical Data

The historical data trend for Jazz Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Accounts Payable Chart

Jazz Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

41.16

22.15

88.76

85.68

94.22

Jazz Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															117.17	90.85	102.93	94.22	74.50

Jazz Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Jazz Pharmaceuticals Accounts Payable Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (STU:J7Z) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

JAZZ:USA JAZZ:Mexico J7Z:Germany

Address

Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7

Website

https://www.jazzpharmaceuticals.com

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (STU:J7Z) Headlines

No Headlines